On October 12, 2006, Roboisson, Pierre; Marugan Sanchez, Juan Jose published a patent.COA of Formula: C15H22N2O3 The title of the patent was Preparation of 4-substituted indoles for use as integrin antagonists. And the patent contained the following:
4-Substituted indoles I, wherein R is Ph or 3-pyridyl; X-Y is -CH2-O-, -CH2-NH-, or -CH2-CH2-; W can be II or III wherein R1 is hydrogen, alkyl, haloalkyl or halogen; R2 and R3 are independently hydrogen, halogen or alkyl; R4 and R5 are independently hydrogen, halogen, alkyl, alkoxy or aryl; R6 is hydrogen are prepared . Thus, IV was prepared and tested integrin antagonists, however, no biol. data was provided. Further, I may be used in the treatment of pathol. conditions mediated by avss3 and avss5 integrins, including but not limited to tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).COA of Formula: C15H22N2O3
The Article related to integrin antagonist human indole, indole preparation integrin antagonist, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.COA of Formula: C15H22N2O3
Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem